Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 174

1.

Measuring enzymatic HIV-1 susceptibility to two reverse transcriptase inhibitors as a rapid and simple approach to HIV-1 drug-resistance testing.

Hoffmann D, Garcia AD, Harrigan PR, Johnston IC, Nakasone T, García-Lerma JG, Heneine W.

PLoS One. 2011;6(7):e22019. doi: 10.1371/journal.pone.0022019. Epub 2011 Jul 20.

PMID:
21799767
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC).

García Lerma J, Schinazi RF, Juodawlkis AS, Soriano V, Lin Y, Tatti K, Rimland D, Folks TM, Heneine W.

Antimicrob Agents Chemother. 1999 Feb;43(2):264-70.

PMID:
9925516
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.

Borroto-Esoda K, Parkin N, Miller MD.

Antivir Chem Chemother. 2007;18(5):297-300.

PMID:
18046962
[PubMed - indexed for MEDLINE]
4.

Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.

Feng JY, Myrick FT, Margot NA, Mulamba GB, Rimsky L, Borroto-Esoda K, Selmi B, Canard B.

Nucleosides Nucleotides Nucleic Acids. 2006;25(1):89-107.

PMID:
16440988
[PubMed - indexed for MEDLINE]
5.

N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.

Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, Wynhoven B, Kuiper M, Sluis-Cremer N, Harrigan PR, Tachedjian G.

PLoS Med. 2007 Dec;4(12):e335.

PMID:
18052601
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.

Liu J, Yue J, Wu S, Yan Y.

Arch Virol. 2007;152(10):1799-805. Epub 2007 Jul 6.

PMID:
17619115
[PubMed - indexed for MEDLINE]
7.

Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.

Miller MD, Haddad M, Su C, Gibbs C, McColl DJ, Guyer B.

Antivir Ther. 2012;17(6):993-9. doi: 10.3851/IMP2266. Epub 2012 Jul 26.

PMID:
22837442
[PubMed - indexed for MEDLINE]
8.

Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.

Brehm JH, Koontz DL, Wallis CL, Shutt KA, Sanne I, Wood R, McIntyre JA, Stevens WS, Sluis-Cremer N, Mellors JW; CIPRA-SA Project 1 Study Team.

Clin Infect Dis. 2012 Sep;55(5):737-45. Epub 2012 May 22.

PMID:
22618567
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.

Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, Deeks SG, Bates M, Hellmann NS, Petropoulos CJ.

AIDS. 2002 Oct 18;16(15):F41-7.

PMID:
12370521
[PubMed - indexed for MEDLINE]
10.

Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma.

Vázquez-Rosales G, García Lerma JG, Yamamoto S, Switzer WM, Havlir D, Folks TM, Richman DD, Heneine W.

AIDS Res Hum Retroviruses. 1999 Sep 1;15(13):1191-200.

PMID:
10480632
[PubMed - indexed for MEDLINE]
11.

Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda.

Towler WI, Barlow-Mosha L, Church JD, Bagenda D, Ajuna P, Mubiru M, Musoke P, Eshleman SH.

AIDS Res Hum Retroviruses. 2010 May;26(5):563-8. doi: 10.1089/aid.2009.0164.

PMID:
20455758
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.

Balzarini J, De Clercq E, Carbonez A, Burt V, Kleim JP.

AIDS Res Hum Retroviruses. 2000 Apr 10;16(6):517-28.

PMID:
10777142
[PubMed - indexed for MEDLINE]
13.

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.

Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, Castelnuovo B, Schaefer P, Spacek LA, Gasasira AF, Katabira E, Colebunders R, Quinn TC, Ronald A, Thomas DL, Kekitiinwa A; Academic Alliance for AIDS Care and Prevention in Africa.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):187-93.

PMID:
17693883
[PubMed - indexed for MEDLINE]
14.

Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.

Rath BA, Olshen RA, Halpern J, Merigan TC.

Viruses. 2012 Aug;4(8):1212-34. Epub 2012 Aug 7.

PMID:
23012621
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.

Gao HQ, Boyer PL, Sarafianos SG, Arnold E, Hughes SH.

J Mol Biol. 2000 Jul 7;300(2):403-18.

PMID:
10873473
[PubMed - indexed for MEDLINE]
16.

Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz.

McColl DJ, Margot N, Chen SS, Harris J, Borroto-Esoda K, Miller MD.

HIV Clin Trials. 2011 Mar-Apr;12(2):61-70. doi: 10.1310/hct1202-61.

PMID:
21498149
[PubMed - indexed for MEDLINE]
17.

Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.

Rajesh L, Karunaianantham R, Narayanan PR, Swaminathan S.

AIDS Res Hum Retroviruses. 2009 Nov;25(11):1179-85. doi: 10.1089/aid.2009.0110.

PMID:
19895208
[PubMed - indexed for MEDLINE]
18.

Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.

Pérez H, Vignoles M, Laufer N, Gómez A, Coll P, Lottner J, Rolón M, Salomón H, Cahn P.

Antivir Ther. 2008;13(1):135-9.

PMID:
18389908
[PubMed - indexed for MEDLINE]
19.

Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.

Chi BH, Ellis GM, Chintu N, Cantrell RA, Sinkala M, Aldrovandi GM, Warrier R, Mbewe F, Nakamura K, Stringer EM, Frenkel LM, Stringer JS.

AIDS Res Hum Retroviruses. 2009 Nov;25(11):1099-106. doi: 10.1089/aid.2009.0088.

PMID:
19886836
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].

Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL, Rando RF.

Antivir Chem Chemother. 2000 Jul;11(4):291-301.

PMID:
10950391
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk